The prognostic role of 1q21 gain/amp in newly diagnosed multiple myeloma: the faster, the worse

被引：0
|
作者：
Wang, Yawen [1 ]
Xu, Jiadai [1 ]
Liu, Peng [1 ]
Li, Panpan [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-227
引用
收藏
页码：S160 / S160
页数：1
相关论文
共 50 条
  • [41] Clinical and biological characteristics of multiple myeloma with 1q21 amplification
    钟仕贞
    China Medical Abstracts(Internal Medicine), 2016, 33 (02) : 52 - 52
  • [42] Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
    Gao, Wen
    Jian, Yuan
    Du, Juan
    Li, Xiaozhe
    Zhou, Huixing
    Zhang, Zhiyao
    Yang, Guangzhong
    Wang, Guorong
    Tian, Ying
    Li, Yanchen
    Wu, Yin
    Fu, Weijun
    Li, Juan
    Chen, Wenming
    CANCER MEDICINE, 2020, 9 (21): : 7819 - 7829
  • [43] Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials
    Chen, Liang
    Li, Zhendong
    Li, Shanshan
    Fu, Weijun
    Li, Rong
    JOURNAL OF CANCER, 2020, 11 (09): : 2639 - 2644
  • [44] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Yuanyuan Jin
    Xiaochen Yu
    Jianhua Du
    Hui Li
    Wenjiao Tang
    Congwei Jia
    Yunyan Zan
    Miao Chen
    Yanbin Zhang
    Minhong Yu
    Weiqi Rong
    Daobin Zhou
    Junling Zhuang
    Annals of Hematology, 2021, 100 : 1251 - 1260
  • [45] 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
    Du, Chenxing
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Yuan, Chenglu
    Du, Xin
    Liu, Jiahui
    Fan, Huishou
    Wang, Qi
    Sui, Weiwei
    Deng, Shuhui
    Fu, Mingwei
    Li, Zengjun
    Li, Chengwen
    Zhao, Jiawei
    Yi, Shuhua
    Liu, Lanting
    Hao, Mu
    Zou, Dehui
    Zhao, Yaozhong
    Qiu, Lugui
    An, Gang
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1201 - 1210
  • [46] The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
    Jin, Yuanyuan
    Yu, Xiaochen
    Du, Jianhua
    Li, Hui
    Tang, Wenjiao
    Jia, Congwei
    Zan, Yunyan
    Chen, Miao
    Zhang, Yanbin
    Yu, Minhong
    Rong, Weiqi
    Zhou, Daobin
    Zhuang, Junling
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1251 - 1260
  • [47] HIGH LEVELS OF NEURAL STEM CELL MARKER NESTIN ARE ASSOCIATED WITH 1Q21 GAIN AND PREDICT WORSE RESPONSE TO CONVENTIONAL AND NOVEL THERAPY IN MULTIPLE MYELOMA
    Svachova, H.
    Kryukov, F.
    Dementyeva, E.
    Kubiczkova, L.
    Sevcikova, S.
    Nemec, P.
    Greslikova, H.
    Kovarova, L.
    Zahradova, L.
    Hajek, R.
    HAEMATOLOGICA, 2012, 97 : 356 - 356
  • [48] Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma
    Yang, Peiyu
    Chen, Haimin
    Liang, Xinyue
    Xu, Weiling
    Yu, Shanshan
    Huang, Wenyang
    Yi, Xingcheng
    Guo, Qiang
    Tian, Mengru
    Yue, Tingting
    Li, Mengyao
    Zhang, Yingjie
    Zhang, Mengxue
    Yan, Yurong
    Hu, Zhongli
    Kumar, Shaji K.
    Zhou, Fan
    Dai, Yun
    Jin, Fengyan
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 251 - 263
  • [49] Hepatitis B virus infection and 1q21 amplification in multiple myeloma
    Guo, Dan
    Xu, Peipei
    Guan, Chaoyang
    Xu, Yong
    Yang, Yonggong
    Xu, Jingyan
    Zhou, Rongfu
    Chen, Bing
    ONCOLOGY LETTERS, 2019, 18 (06) : 6196 - 6206
  • [50] ILF2 IS UPREGULATED BY 1Q21 AMPLIFICATION IN MULTIPLE MYELOMA
    不详
    CANCER DISCOVERY, 2017, 7 (08) : 795 - 795
12345